Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
None (2) ·
Alprazolam (1) ·
Bromazepam (1) ·
Bromazolam (1) ·
Chlordiazepoxide (1) ·
Clobazam (1) ·
Clonazolam (1) ·
Clorazepate (1) ·
Deschloroetizolam (1) ·
Diclazepam (1) ·
Estazolam (1) ·
Eszopiclone (1) ·
Ethchlorvynol (1) ·
Flualprazolam (1) ·
Flubromazepam (1) ·
Flubromazolam (1) ·
Flunitrazepam (1) ·
Flunitrazolam (1) ·
Flurazepam (1) ·
Gaboxadol (1) ·
GHB (1) ·
Glutethimide (1) ·
Lormetazepam (1) ·
Methaqualone (1) ·
Midazolam (1) ·
Nifoxipam (1) ·
Nitrazepam (1) ·
Oxazepam (1) ·
Pentobarbital (1) ·
Pyrazolam (1) ·
Quazepam (1) ·
Ramelteon (1) ·
Secobarbital (1) ·
Tasimelteon (1) ·
Temazepam (1) ·
Triazolam (1) ·
Zaleplon (1) ·
Zopiclone (1)
None (10) ·
(none, never marketed) (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Lexotan (1) ·
Librium (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Onfi (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Serax (1) ·
Sonata (1) ·
Sunosi (1) ·
THIP (1) ·
Tranxene (1) ·
Versed (1) ·
Wakix (1) ·
Xanax (1) ·
Xyrem (1)
None (3) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (19) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Melatonin receptor agonist (2) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1)
None (35) ·
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) ·
Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019) (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
None (35) ·
0.25 mg (1) ·
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed. (1)
None (35) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
4.45 mg, 17.8 mg tablets (1) ·
75 mg, 150 mg tablets (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
None (35) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Limited data; pitolisant may reduce hormonal contraceptive efficacy (1) ·
Limited data; pregnancy exposure registry available (1)
Showing below up to 55 results in range #1 to #55.
A
B
C
D
E
F
- Flubromazolam
- Flubromazolam
- Flunitrazepam
- Flunitrazepam
- Flunitrazolam
- Flunitrazolam
- Flurazepam
- Flurazepam


